BioSpace News Archive

PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has solidified its leadership position in the EU with strategic investment to deepen its presence in Ireland and expand its European foothold.

“Hepatitis C virus remains a significant public health issue, but effective therapeutic options have helped patients to receive important curative treatments,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products within the FDA’s Center for Drug Evaluation and Research.

The Crohn’s & Colitis Foundation’s New England Chapter proudly announces its 50th anniversary, commemorating five decades of volunteer leadership, research initiatives, disease awareness, patient support, and advocacy programs.

According to a new guideline, the answer is yes. The guideline, developed by the American Academy of Neurology (AAN), recommends that people with MS receive recommended vaccinations, including yearly flu shots.

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular’s remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how.

REGENXBIO Inc. announced that it will present at the following September investor conferences

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare Conference, in Boston, MA.

Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., today announced the expansion of its SolutionsHub with CueSquared MobilePay™, a new platform that augments the collection efforts of patient self-pay balances, allowing patients to access and pay their bills anywhere, at any time

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today reported financial results for the quarter ended June 30, 2019 and provided an update on its clinical programs.

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley’s Annual Global Healthcare Conference in New York, NY on Monday, September 9, 2019 at 11:05am Eastern time.